Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/27014 
Erscheinungsjahr: 
2007
Schriftenreihe/Nr.: 
Kiel Advanced Studies Working Papers No. 437
Verlag: 
Kiel Institute for the World Economy (IfW), Kiel
Zusammenfassung: 
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when investigating the impact of indirect price controls. Our results show that Germany (65%) has the highest probability of experiencing an early launch, while it is the lowest in southern European countries (18% for Portugal and 19% for Greece). This difference accrues from both price regulation and market attractiveness, since southern European countries generally have lower prices. Due to the possibilities for parallel trade within the EU, pharmaceutical companies, by acting strategically, may further increase launch delays.
Schlagwörter: 
pharmaceuticals
regulation
new chemical entity
parallel trade
JEL: 
I11
I18
L51
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
207.42 kB





Publikationen in EconStor sind urheberrechtlich geschützt.